Smoldering Multiple Myeloma — Trials

Smoldering Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

85 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 34
Recruiting: 13
Ph III recruiting: 1
Growth YoY: —
Industry share: 9%
Top sponsor: Dana-Farber Cancer Institute
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05469893	Immuno-PRISM (PRecision Intervention Smoldering Myeloma)	recruiting	Phase 2	52	Irene Ghobrial, MDOTHER	1	Jul 16, 2026	clinicaltrials
NCT06140524	A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma(LINKER-MGUS1)	recruiting	Phase 2	116	Regeneron PharmaceuticalsINDUSTRY	7